BioNxt Solutions Inc. (CVE:BNXT)

BRIEF

published on 10/09/2025 at 09:10, 6 months 21 days ago

BioNxt Completes Fast-Track Patent Filing for MS Treatment

Multiple Sclerosis Cladribine Patent Filing BioNxt Solutions Sublingual Delivery
PRESS RELEASE

published on 10/09/2025 at 09:05, 6 months 21 days ago

BioNxt Completes "Fast-Track" US Track One Patent Filing for Sublingual Delivery of Cladribine for the Treatment of Multiple Sclerosis
BioNxt Solutions Inc. completes Track One priority patent filing with USPTO for sublingual thin-film cladribine formulation (BNT23001) targeting MS & other autoimmune diseases. Strategic move to strengthen IP position & advance regulatory approvals

BioNxt Solutions Inc. Multiple Sclerosis Patent Filing Sublingual Thin-Film Cladribine Formulation
BRIEF

published on 10/02/2025 at 09:10, 6 months 28 days ago

BioNxt Advances Targeted Chemotherapy Drug Delivery Platform

Biopharmaceutical Drug Delivery Research Advancements BioNxt Solutions Targeted Chemotherapy
PRESS RELEASE

published on 10/02/2025 at 09:05, 6 months 28 days ago

BioNxt Reports Update on Targeted Chemotherapy Drug Delivery Platform
BioNxt Solutions Inc. reports significant advancement in targeted chemotherapy delivery platform and upcoming definitive agreement. Proprietary technology aims at 10-fold increase in therapeutic effect while safeguarding healthy cells

BioNxt Solutions Inc. Oncology Treatments Chemotherapy Delivery Platform Targeted Drug Delivery System Therapeutic Effect
BRIEF

published on 09/29/2025 at 09:10, 7 months 1 day ago

BioNxt Advances Cladribine Sublingual Drug Development for Multiple Sclerosis

Drug Development Multiple Sclerosis Cladribine Bioavailability Sublingual
PRESS RELEASE

published on 09/29/2025 at 09:05, 7 months 1 day ago

BioNxt Reports Sublingual Cladribine Multiple Sclerosis Drug Milestones Including Large-Animal Study for Validation and Dosing Optimization
BioNxt Solutions provides update on Cladribine sublingual thin-film drug reformulation program, targeting treatment of multiple sclerosis with improved bioavailability and patient adherence

Multiple Sclerosis Cladribine Neurological Disorders BioNxt Solutions Drug Delivery Technologies
BRIEF

published on 09/20/2025 at 03:50, 7 months 10 days ago

BioNxt Solutions Completes Shares for Debt Settlement

Common Shares Debt Settlement Debt Agreement Canadian Securities BioNxt Solutions
PRESS RELEASE

published on 09/20/2025 at 03:45, 7 months 10 days ago

BioNxt Solutions Announces Closing of Shares for Debt Settlement
BioNxt Solutions Inc. announces successful debt settlement with creditor, issuing common shares and making cash payment. Company focuses on bioscience innovation and drug delivery technologies

Common Shares Debt Settlement BioNxt Solutions Inc. Drug Delivery Technologies Bioscience Innovation
BRIEF

published on 09/20/2025 at 01:35, 7 months 10 days ago

BioNxt Solutions Inc. Engages Capital Markets Advisor and Investor Relations Professionals

Stock Options Investor Relations Capital Markets BioNxt Solutions Terry Lynch
PRESS RELEASE

published on 09/20/2025 at 01:30, 7 months 10 days ago

Terry Lynch Continues as Capital Markets Advisor and BioNxt Retains Investor Relations Professionals
BioNxt Solutions Inc. announces Terry Lynch as capital markets advisor and retention of two investor relations professionals, Rob Grace and Blaine Ruzcki, for promotional activities. Company focuses on bioscience innovations with drug delivery platforms

BioNxt Solutions Inc. Terry Lynch Investor Relations Professionals Bioscience Innovations Drug Delivery Platforms

Published on 04/30/2026 at 13:30, 45 minutes ago

Silver X Delivers Strong 2025 Financial Results with Margin Expansion and Clear Path to Growth
Published on 04/30/2026 at 13:30, 45 minutes ago

Electric Metals Expands Investor Outreach with Multi-Channel Engagement Across North America and Europe
Published on 04/30/2026 at 13:23, 52 minutes ago

Slam Drilling 40.5 g/t Gold Vein on the Jake Lee Gold Project
Published on 04/30/2026 at 13:00, 1 hour 15 minutes ago

RK Equity Initiates Research Coverage on NOA Lithium
Published on 04/30/2026 at 13:00, 1 hour 15 minutes ago

Earthwise Minerals Approves 2026 Drill Program to Advance Talon Zone at Iron Range Gold Project

View all ACCESSWIRE

Published on 04/30/2026 at 14:05, 10 minutes ago

Claros Demonstrates ≥99.99% PFAS Destruction in Groundwater from MPCA Lake Elmo Site
Published on 04/30/2026 at 14:00, 15 minutes ago

Diginex Issues Corporate Update Highlighting Strategic AI Transformation, $1.5 Billion Resulticks Acquisition with Strong EBITDA Profile of US$46–50 Million, and Disciplined Funded Growth Strategy
Published on 04/30/2026 at 13:47, 27 minutes ago

EQS-Adhoc: INDUS Holding AG adjusts its guidance for the 2026 financial year
Published on 04/30/2026 at 13:15, 1 hour ago

ESTEVE'S EXPANSION AND GROWTH IN EU AND USA ACCELERATES ITS TRANSFORMATION INTO A GLOBAL HEALTHCARE COMPANY
Published on 04/30/2026 at 13:15, 1 hour ago

USTA to Feature PlayReplay Electronic Line-Calling at all USTA Pro Circuit Men's and Women's ITF World Tennis Tour Hard-Court Events over the Next Five Years

View all EQS

Published on 04/30/2026 at 07:45, 6 hours 30 minutes ago

The Belgian State and ENGIE Group enter into exclusive negotiations for the acquisition by Belgium of ENGIE's nuclear activities
Published on 04/30/2026 at 07:30, 6 hours 45 minutes ago

New Gimv Anchor investment: acquisition of 5% shareholding in Azelis
Published on 04/30/2026 at 07:29, 6 hours 46 minutes ago

First Quarter Revenues 2026
Published on 04/29/2026 at 23:00, 15 hours 15 minutes ago

INFORMATION ON ANNUAL FINANCIAL STATEMENTS
Published on 04/29/2026 at 18:31, 19 hours 43 minutes ago

FIRST QUARTER 2026 TURNOVER

View all LES ECHOS COMFI WIRE

News